Loading clinical trials...

A Multiple Dose Study of DWP05195 in Healthy Adult Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Multiple Dose Study of DWP05195 in Healthy Adult Subjects

A Multiple Dose Study To Determine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP05195 in Healthy Adult Subjects

NCT01094834•Daewoong Pharmaceutical Co. LTD.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple administered DWP05195 in healthy volunteers

Eligibility

Age

20 - 45 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. Healthy adult male subjects aged 20 to 45 years
•2. The subject has a Body weight ≥50 kg and \<90 kg and Body Mass Index(BMI) ≥19.0 kg/m2 and \< 27.0 kg/m2.
•3. A subject who provided written informed consent to participate in this study and cooperative with regard to compliance with study related constraints
•4. A Subject who was judged to be healthy by the investigator to participate in this study based on screening results (according to standard reference index updated recently)

Exclusion Criteria

•1\. A subject with sign or symptoms or previously diagnosed disease of respiratory, cardiovascular, endocrinology, liver, kidney, gastrointestinal, hematology, neurology and psychology function or other significant diseases and history or suspicion of current drug abuse and alcohol abuse 2. A subject who had any allergic history to any drug (prescription drug or OTC medication etc.) 3. A subject who had received treatment with below listed drug within specified period prior to the first dose of study medication
•Within last 1 month : drug or food known CYP1A2 inducer or inhibitor
•Within 2 weeks : Prescribed or herbal or Non-prescribed medicine
•Within 3 days : Consumption of grapefruit juice/grapefruit containing products or orange juice/orange containing products, garlic extracted functional foods
•Within 3 days : Consumption of alcohol or caffeine 4. A subject who had participated in any other clinical study within the last 12 weeks 5. A subject from whom over 400mL of blood was sampled(whole blood or plasma donation, etc.) within last 12 weeks 6. A Subject with the known evidence of the following infections or drug abuse
•HIV, HBs, HCV
•cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine 7. Smoker or smoking cessation within 1 month or ex-smoker with positive results by cotinine test 8. AST or ALT greater than 1.5 times the upper limit of reference range or QTc \> 430 msec base on screening results 9. Blood pressure : SBP≥140mmHg, DBP≤85mmHg 10. A subject judged ineligible by the investigator to participate in this study for other reason containing clinical laboratory tests

Key Dates

Start Date

April 1, 2010

Primary Completion Date

October 1, 2010

Last Updated

February 9, 2011

Enrollment

ESTIMATED participants

Conditions

Healthy Adult Volunteers

Interventions

DWP05195

DRUG

A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis

NCT06681389

Healthy Adult VolunteersActive Ulcerative Colitis+1 more

View study

COMPLETEDEARLY_PHASE1

A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers

NCT04204772

Healthy Adult Volunteers

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions